{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:47:21Z","timestamp":1792784841152,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Key Project of Shanghai Pulmonary Hospital","id":[{"id":"https:\/\/ror.org\/033nbnf69","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02984-y","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:37:19Z","timestamp":1791970639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Camrelizumab plus chemotherapy as induction therapy followed by concurrent chemoradiotherapy and camrelizumab consolidation in limited-stage small cell lung cancer: a randomized phase II trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Di","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-0766","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2984_CR1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/jama.2025.0560","volume":"333","author":"SY Kim","year":"2025","unstructured":"Kim, S. Y., Park, H. S. & Chiang, A. C. Small cell lung cancer: a review. JAMA 333, 1906\u20131917 (2025).","journal-title":"JAMA"},{"key":"2984_CR2","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-2600(24)00223-6","volume":"12","author":"FL Schneiders","year":"2024","unstructured":"Schneiders, F. L. & Senan, S. New strategies for patients with limited-stage small-cell lung cancer. Lancet Respir. Med. 12, 748\u2013750 (2024).","journal-title":"Lancet Respir. Med."},{"key":"2984_CR3","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","volume":"327","author":"J-P Pignon","year":"1992","unstructured":"Pignon, J.-P. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327, 1618\u20131624 (1992).","journal-title":"N. Engl. J. Med."},{"key":"2984_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung cancer. Nat. Rev. Dis. Prim. 7, 3 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2984_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N. Engl. J. Med. 379, 2220\u20132229 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2984_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares, L. et al. Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929\u20131939 (2019).","journal-title":"Lancet"},{"key":"2984_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1200\/JCO.21.01881","volume":"40","author":"J Zugazagoitia","year":"2022","unstructured":"Zugazagoitia, J. & Paz-Ares, L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J. Clin. Oncol. 40, 671\u2013680 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2984_CR8","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301\u20131311 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2984_CR9","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.21037\/tlcr-20-608","volume":"9","author":"Q Zhou","year":"2020","unstructured":"Zhou, Q. et al. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced\/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent\/sequential chemoradiotherapy. Transl. Lung Cancer Res. 9, 2008\u20132015 (2020).","journal-title":"Transl. Lung Cancer Res."},{"key":"2984_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","volume":"391","author":"Y Cheng","year":"2024","unstructured":"Cheng, Y. et al. Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N. Engl. J. Med. 391, 1313\u20131327 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2984_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41568-025-00803-0","volume":"25","author":"KL Simpson","year":"2025","unstructured":"Simpson, K. L., Rothwell, D. G., Blackhall, F. & Dive, C. Challenges of small cell lung cancer heterogeneity and phenotypic plasticity. Nat. Rev. Cancer 25, 447\u2013462 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"2984_CR12","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.jtho.2020.08.022","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh, J. W. et al. Phase 1\/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC. J. Thorac. Oncol. 15, 1919\u20131927 (2020).","journal-title":"J. Thorac. Oncol."},{"key":"2984_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaoncol.2021.2301","volume":"7","author":"SK Jabbour","year":"2021","unstructured":"Jabbour, S. K. et al. Pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer: the phase 2 KEYNOTE-799 nonrandomized trial. JAMA Oncol. 7, 1\u20139 (2021).","journal-title":"JAMA Oncol."},{"key":"2984_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1200\/JCO-25-01569","volume":"44","author":"KA Higgins","year":"2026","unstructured":"Higgins, K. A. et al. Chemoradiation \u00b1 atezolizumab in limited-stage small cell lung cancer: results of NRG oncology\/alliance LU005. J. Clin. Oncol. 44, 630\u2013640 (2026).","journal-title":"J. Clin. Oncol."},{"key":"2984_CR15","doi-asserted-by":"publisher","first-page":"TPS8587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8587","volume":"39","author":"A Rimner","year":"2021","unstructured":"Rimner, A. et al. KEYLYNK-013: a phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC. J. Clin. Oncol. 39, TPS8587\u2013TPS8587 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2984_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382\u20131399 (2016).","journal-title":"Cancer Discov."},{"key":"2984_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.501","volume":"5","author":"L Wu","year":"2024","unstructured":"Wu, L. et al. Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non-small cell lung cancer: a multi-institutional retrospective cohort study. MedComm 5, e501 (2024).","journal-title":"MedComm"},{"key":"2984_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.annonc.2021.09.011","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters, S. et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy\u2014results from the randomised phase II ETOP\/IFCT 4-12 STIMULI trial. Ann. Oncol. 33, 67\u201379 (2022).","journal-title":"Ann. Oncol."},{"key":"2984_CR19","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","volume":"111","author":"S Diem","year":"2017","unstructured":"Diem, S. et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 111, 176\u2013181 (2017).","journal-title":"Lung Cancer"},{"key":"2984_CR20","doi-asserted-by":"publisher","first-page":"1408700","DOI":"10.3389\/fimmu.2024.1408700","volume":"15","author":"S Tan","year":"2024","unstructured":"Tan, S. et al. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Front. Immunol. 15, 1408700 (2024).","journal-title":"Front. Immunol."},{"key":"2984_CR21","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00262-020-02706-5","volume":"70","author":"Q Xiong","year":"2021","unstructured":"Xiong, Q. et al. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1\/PD-L1 antibody in SCLC patients at early phase. Cancer Immunol. Immunother. 70, 713\u2013720 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"1482746","DOI":"10.3389\/fimmu.2024.1482746","volume":"15","author":"Y Ou","year":"2024","unstructured":"Ou, Y. et al. Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Front. Immunol. 15, 1482746 (2024).","journal-title":"Front. Immunol."},{"key":"2984_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3390\/cancers15010257","volume":"15","author":"R Minici","year":"2022","unstructured":"Minici, R. et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: the unexplored corner linking tumor microenvironment, biomarkers and interventional radiology. Cancers 15, 257 (2022).","journal-title":"Cancers"},{"key":"2984_CR24","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2021.11.021","volume":"163","author":"AK Bryant","year":"2022","unstructured":"Bryant, A. K. et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer 163, 35\u201341 (2022).","journal-title":"Lung Cancer"},{"key":"2984_CR25","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1007\/s00018-013-1286-4","volume":"70","author":"J Pillay","year":"2013","unstructured":"Pillay, J., Tak, T., Kamp, V. M. & Koenderman, L. Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences. Cell. Mol. Life Sci. 70, 3813\u20133827 (2013).","journal-title":"Cell. Mol. Life Sci."},{"key":"2984_CR26","doi-asserted-by":"publisher","first-page":"e31524","DOI":"10.1371\/journal.pone.0031524","volume":"7","author":"ZG Fridlender","year":"2012","unstructured":"Fridlender, Z. G. et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PLoS ONE 7, e31524 (2012).","journal-title":"PLoS ONE"},{"key":"2984_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis, R. J., Van Waes, C. & Allen, C. T. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral. Oncol. 58, 59\u201370 (2016).","journal-title":"Oral. Oncol."},{"key":"2984_CR28","doi-asserted-by":"publisher","first-page":"101229","DOI":"10.1016\/j.tranon.2021.101229","volume":"14","author":"CD Spillane","year":"2021","unstructured":"Spillane, C. D. et al. The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon. Transl. Oncol. 14, 101229 (2021).","journal-title":"Transl. Oncol."},{"key":"2984_CR29","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.3390\/ph15121532","volume":"15","author":"KR Xulu","year":"2022","unstructured":"Xulu, K. R. & Augustine, T. N. Targeting platelet activation pathways to limit tumour progression: current state of affairs. Pharmaceuticals 15, 1532 (2022).","journal-title":"Pharmaceuticals"},{"key":"2984_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3233\/CBM-160336","volume":"19","author":"J Ding","year":"2017","unstructured":"Ding, J., Karp, J. E. & Emadi, A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 19, 353\u2013363 (2017).","journal-title":"Cancer Biomark."},{"key":"2984_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256\u2013261 (2016).","journal-title":"Br. J. Cancer"},{"key":"2984_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44178-023-00067-4","volume":"3","author":"X Zhi","year":"2024","unstructured":"Zhi, X. et al. Correlation of lung immune prognostic index with the efficacy of immune checkpoint inhibitors in Chinese patients with advanced non-small cell lung cancer. Holist. Integ. Oncol. 3, 2 (2024).","journal-title":"Holist. Integ. Oncol."},{"key":"2984_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2022.11.032","volume":"181","author":"TBS Miholjcic","year":"2023","unstructured":"Miholjcic, T. B. S. et al. Rationale for LDH-targeted cancer immunotherapy. Eur. J. Cancer 181, 166\u2013178 (2023).","journal-title":"Eur. J. Cancer"},{"key":"2984_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s44178-024-00121-9","volume":"3","author":"W Ma","year":"2024","unstructured":"Ma, W. et al. Advances in predictive biomarkers for melanoma immunotherapy. Holist. Integ. Oncol. 3, 48 (2024).","journal-title":"Holist. Integ. Oncol."},{"key":"2984_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14445-w","volume":"25","author":"X Zhang","year":"2025","unstructured":"Zhang, X., He, M., Zheng, G. & Bai, J. The impact of stratified management of Ki-67 on the prognosis of small-cell lung cancer. BMC Cancer 25, 1197 (2025).","journal-title":"BMC Cancer"},{"key":"2984_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ijrobp.2022.02.003","volume":"113","author":"KH Kim","year":"2022","unstructured":"Kim, K. H. et al. Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1\/PD-L1 therapy. Int. J. Radiat. Oncol.*Biol.*Phys. 113, 415\u2013425 (2022).","journal-title":"Int. J. Radiat. Oncol.*Biol.*Phys."},{"key":"2984_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187, 184\u2013203 (2024).","journal-title":"Cell"},{"key":"2984_CR38","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1016\/j.cell.2025.03.018","volume":"188","author":"Z Liu","year":"2025","unstructured":"Liu, Z. et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell 188, 3081\u20133096 (2025).","journal-title":"Cell"},{"key":"2984_CR39","unstructured":"Amin, M. B. et al. AJCC cancer staging manual. AJCC cancer staging manual 8th ed (2017)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02984-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02984-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02984-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:37:22Z","timestamp":1791970642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02984-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02984-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"448"}}